DocuSign heads into its June 1 earnings with short sellers rebuilding positions against a stock that has quietly recovered 9% on the week — and options traders turning more defensive than they have been in months.
The short story is more active than the headline number suggests. Short interest has climbed back to 8.2% of the free float, up from a trough around 7.4% in early May. That's a meaningful reversal after a sharp unwind in late April, when SI fell from roughly 9.5% — a multi-week high set around April 13 — to under 7.7% by the final week of the month. Bears re-engaged through May, adding roughly 1.4 million shares to the position over the past fortnight. Still, borrowing conditions offer little friction: cost to borrow has ticked higher over the week but remains low at 0.43%, and availability is effectively uncapped, with the lending pool vastly oversupplied relative to short demand. There is no squeeze pressure here.
Options tell a more cautious story than the lending market does. The put/call ratio is running well above its recent average at 0.86, nearly two standard deviations above the 20-day mean of 0.81. That's not yet at the defensive extreme — the 52-week high is 1.07 — but the jump is notable given that the PCR had been anchored in a narrow band for most of April. Investors appear to be adding downside protection into the June print even as the stock catches a bid.
The Street is not enthusiastic. The consensus is a firm hold, with just two buy ratings against sixteen holds. Citigroup moved the most dramatically in early April, cutting from Buy to Neutral and slashing its target from $99 to $50 — now almost exactly where the stock trades. The broader wave of downgrades came in mid-March, when JPMorgan, Morgan Stanley, UBS, Wells Fargo, and Baird all maintained neutral stances while trimming targets by 20–30%. BofA reinstated with an Underperform in late March. The mean target of roughly $60 implies modest upside from the current $49.42 price, but the target cluster has compressed sharply and the recent trajectory of estimate revisions has been downward. The EV/EBITDA multiple has drifted up to 7.3x over the past month, a small re-rating on the back of the price recovery, but the P/E of 10.6x keeps DocuSign well inside value territory for a SaaS name. The 90-day EPS momentum factor ranks in the 72nd percentile, suggesting forward estimates have been relatively stable even as near-term surprise history scores at just the 35th percentile.
Institutional flow offers one contrasting signal. Capital Research and Management added over 1.2 million shares in the quarter ending March 31, while AQR added 3.4 million and Arrowstreet built a position of 2.3 million new shares. Millennium also added 1.3 million. Against that, Jericho Capital trimmed by 1.75 million shares — a notable reduction from a holder that had built a 3 million share stake. The cluster of institutional buying from quant and multi-manager funds suggests technical and model-driven interest, not necessarily a fundamental re-rating thesis.
Among correlated peers, LiveRamp surged 31% on the week while nCino fell 7%. DocuSign's 9% move sits firmly in the middle of that range, which is a meaningful improvement on the prior note's theme of persistent underperformance relative to the SaaS cohort. What to watch on June 1 is whether management's commentary on IAM adoption rates and Agreement Cloud attach gives investors a reason to revisit the holding pattern — or whether the conservative guidance trend that has characterised recent prints continues to anchor the multiple.
See the live data behind this article on ORTEX.
Open DOCU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
